MorphoSys, Novartis, Galapagos abandon experimental MOR106
The decision was based on a “low probability to meet main goal of study.”
30th October 2019
Latest news
AZ divests rights to Seroquel in Europe, Russia
The decision comes as both drugs, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in the areas.
30th October 2019
Benlysta granted European extension
The drug was initially given a NICE nod back in 2016, and cleared by the European regulators back in 2011.
30th October 2019
Social media used to boost cancer screening rates
In an initial pilot that used Facebook to promote breast screening, one area saw a 12.9% increase in the take up of screening services.
30th October 2019
Gilead, Glympse Bio to explore biomarker use in NASH
NASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver, which can lead to scarring, or fibrosis, that impairs liver function.
29th October 2019
Sense Biodetection raises £12.3m for molecular diagnostics
The company will use it to develop its portfolio of instrument-free, point-of-care molecular diagnostic tests.
29th October 2019
EU ‘yes’ for Bavencio
The approval was based on positive interim results from the Phase III JAVELIN Renal 101 study.
29th October 2019
GSK initiates experimental gepotidacin trial
The drug is the first in a new chemical class of antibiotics dubbed "triazaacenaphthylene bacterial topoisomerase inhibitors."
29th October 2019
Late-stage success for Imfinzi in NSCLC
The AstraZeneca human monoclonal antibody binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering a tumour's immune-evading tactics.
29th October 2019
Finalists announced for Marketer of the Year 2019
The finalists for the 2019 Marketer of the Year competition have now done all they can in their bid to be crowned the winner.
29th October 2019
Number of NIHR-supported research participants exceeds 1M
The news marks a “significant milestone."
28th October 2019
NIHR, MRC buddy up to tackle global chronic disease
The organisations announced plans to invest over £6 million in five implementation science projects focused on tackling diabetes and hypertension in low- and middle-income countries.
28th October 2019
AZ commits £28m to tackle non-communicable disease
The plan is designed to inform adolescents in under-resourced communities on how to reduce risky behaviours including smoking, alcohol, poor diet and lack of exercise.
28th October 2019
Tecentriq, Avastin combo trumps Nexavar in liver cancer
Hepatocellular carcinoma is a major cause of cancer deaths worldwide, affecting over 750,000 people every year.
28th October 2019
Gov’t announces social prescribing academy updates
Only 60% of CCGs use social prescribing for patients with anxiety, mental health problems and dementia, despite evidence that it helps.
28th October 2019
